Marshall Wace North America’s Avanos Medical AVNS Stock Holding History

Marshall Wace North America’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,329	Closed	-$277K	–	1448
2021 Q1	$277K	Buy	+6,329	New	+$297K	﹤0.01%	1331
2020 Q4	–	Sell	-14,647	Closed	-$487K	–	1303
2020 Q3	$487K	Sell	14,647 -32,948	-69%	-$1.05M	﹤0.01%	967
2020 Q2	$1.4M	Buy	47,595 +10,785	+29%	+$312K	0.01%	673
2020 Q1	$991K	Buy	+36,810	New	+$1.1M	0.01%	611
2019 Q3	–	Sell	-73,072	Closed	-$3.19M	–	1303
2019 Q2	$3.19M	Buy	73,072 +27,499	+60%	+$1.18M	0.02%	459
2019 Q1	$1.95M	Buy	45,573 +12,768	+39%	+$572K	0.01%	519
2018 Q4	$1.47M	Buy	32,805 +19,709	+150%	+$1.03M	0.01%	519
2018 Q3	$897K	Sell	13,096 -133,901	-91%	-$8.62M	0.01%	619
2018 Q2	$8.42M	Buy	+146,997	New	+$7.77M	0.05%	371

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Marshall Wace North America's AVNS Position: Q2 2021 in Review

Marshall Wace North America sold out of Avanos Medical (AVNS) in Q2 2021, closing a stake of 6,329 shares — an estimated $277K sold.

Marshall Wace North America first reported a position in AVNS in Q2 2018 and held it in 9 quarters. The position peaked at $8.42M in Q2 2018. 274 funds tracked by Wall St. Rank hold AVNS as of Q2 2021.

Marshall Wace North America reported no remaining Avanos Medical position as of Q2 2021 after selling out during the quarter.
Marshall Wace North America sold 6,329 Avanos Medical shares in Q2 2021, an estimated $277K.
Marshall Wace North America first reported a position in Avanos Medical in Q2 2018 and held it in 9 quarters.
Marshall Wace North America's Avanos Medical position peaked at $8.42M in Q2 2018.
274 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.